Literature DB >> 30745415

Targeting Dopamine D2, Adenosine A2A, and Glutamate mGlu5 Receptors to Reduce Repetitive Behaviors in Deer Mice.

Mark H Lewis1, Christopher T Primiani1, Amber M Muehlmann2.   

Abstract

Repetitive behaviors are seemingly purposeless patterns of behavior that vary little in form and are characteristic of many neurodevelopmental, psychiatric, and neurologic disorders. Our work has identified an association between hypofunctioning of the indirect basal ganglia pathway and the expression of repetitive behavior in the deer mouse model. In this study, we targeted indirect pathway cells of the striatum with single drugs and drug combinations that bind to dopamine D2, adenosine A2A, and glutamate mGlu5 receptors. These receptors function both individually and as receptor heteromers. We found that only the triple drug cocktail (L-741,626+CGS21680+CDPPB) that was designed to increase striatal indirect basal ganglia pathway cell function reduced repetitive behavior in adult male deer mice. No single drug or double drug combinations were effective at selectively reducing repetitive behavior. We found this triple drug cocktail reduced repetitive behavior in both short-acting and long-acting formulations and was effective throughout 7 days of daily administration. Conversely, another triple drug cocktail (quinpirole+SCH58261+MTEP) that was designed to further reduce striatal indirect basal ganglia pathway cell function caused a significant increase in repetitive behavior. Significant and behaviorally selective effects on repetitive behavior were only achieved with the triple drug cocktails that included doses of L-741,626 and quinpirole that have off-target effects (e.g., dopamine D3 receptors). These data further a role for decreased indirect basal ganglia pathway activation in repetitive behavior and suggest that targeting these receptors and/or heteromeric complexes on the indirect pathway neurons of the striatum may offer pharmacotherapeutic benefit for individuals with repetitive behavior disorders.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30745415      PMCID: PMC6423618          DOI: 10.1124/jpet.118.256081

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  71 in total

1.  Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice.

Authors:  María Jesús Luque-Rojas; Pablo Galeano; Juan Suárez; Pedro Araos; Luis J Santín; Fernando Rodríguez de Fonseca; Eduardo Blanco Calvo
Journal:  Int J Neuropsychopharmacol       Date:  2012-05-30       Impact factor: 5.176

2.  Indirect basal ganglia pathway mediation of repetitive behavior: attenuation by adenosine receptor agonists.

Authors:  Yoko Tanimura; Sasha Vaziri; Mark H Lewis
Journal:  Behav Brain Res       Date:  2010-02-21       Impact factor: 3.332

3.  Striatal opioid peptide content in an animal model of spontaneous stereotypic behavior.

Authors:  Michael F Presti; Mark H Lewis
Journal:  Behav Brain Res       Date:  2005-02-28       Impact factor: 3.332

4.  Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors.

Authors:  Helen S Bateup; Emanuela Santini; Weixing Shen; Shari Birnbaum; Emmanuel Valjent; D James Surmeier; Gilberto Fisone; Eric J Nestler; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-03       Impact factor: 11.205

5.  The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors.

Authors:  P Popoli; A Pèzzola; M Torvinen; R Reggio; A Pintor; L Scarchilli; K Fuxe; S Ferré
Journal:  Neuropsychopharmacology       Date:  2001-10       Impact factor: 7.853

6.  A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.

Authors:  Gene G Kinney; Julie A O'Brien; Wei Lemaire; Maryann Burno; Denise J Bickel; Michelle K Clements; Tsing-Bau Chen; David D Wisnoski; Craig W Lindsley; Philip R Tiller; Sheri Smith; Marlene A Jacobson; Cyrille Sur; Mark E Duggan; Douglas J Pettibone; P Jeffrey Conn; David L Williams
Journal:  J Pharmacol Exp Ther       Date:  2004-12-17       Impact factor: 4.030

7.  Development of repetitive behavior in a mouse model: roles of indirect and striosomal basal ganglia pathways.

Authors:  Yoko Tanimura; Michael A King; Dustin K Williams; Mark H Lewis
Journal:  Int J Dev Neurosci       Date:  2011-02-15       Impact factor: 2.457

8.  Striatopallidal dysfunction underlies repetitive behavior in Shank3-deficient model of autism.

Authors:  Wenting Wang; Chenchen Li; Qian Chen; Marie-Sophie van der Goes; James Hawrot; Annie Y Yao; Xian Gao; Congyi Lu; Ying Zang; Qiangge Zhang; Katherine Lyman; Dongqing Wang; Baolin Guo; Shengxi Wu; Charles R Gerfen; Zhanyan Fu; Guoping Feng
Journal:  J Clin Invest       Date:  2017-04-17       Impact factor: 14.808

9.  Stereotypy in Autism: The Importance of Function.

Authors:  Allison B Cunningham; Laura Schreibman
Journal:  Res Autism Spectr Disord       Date:  2008

10.  Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.

Authors:  Jill L Silverman; Seda S Tolu; Charlotte L Barkan; Jacqueline N Crawley
Journal:  Neuropsychopharmacology       Date:  2009-12-23       Impact factor: 7.853

View more
  2 in total

1.  Reduction of repetitive behavior by co-administration of adenosine receptor agonists in C58 mice.

Authors:  Mark H Lewis; Hemangi Rajpal; Amber M Muehlmann
Journal:  Pharmacol Biochem Behav       Date:  2019-05-02       Impact factor: 3.533

Review 2.  Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications.

Authors:  Hamideh Zarrinmayeh; Paul R Territo
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.